{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:40:30Z","timestamp":1781264430137,"version":"3.54.1"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T00:00:00Z","timestamp":1148428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atazanavir (ATV), an HIV protease inhibitor (PI) that may be preferred for the treatment of HIV\u2010infected patients with cardiovascular comorbidities because of its favourable effects on plasma lipids, has been associated with cardiac rhythm disturbances.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To quantify the effect of ATV on corrected QT (QTc) and QTc dispersion (QTd), markers of the potential for cardiac dysrhythmia, in patients switching from other PIs to ATV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective, single\u2010centre, open\u2010label study, 12\u2010lead electrocardiograms were performed for subjects at baseline, 2 h after the first dose of ATV, and 1 month after initiation of ATV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010one patients (19 received ritonavir\u2010boosted ATV) completed the study. There was a trend towards an increase in the QTc at 2 h after the first dose [mean\u00b1standard deviation 3.19\u00b18.0 ms; 95% confidence interval (CI) \u22120.47 to 6.85 ms; <jats:italic>P<\/jats:italic>=0.084]. There was no difference between QTc values at baseline and at 1 month (\u22121.5\u00b18.75 ms; 95% CI \u22125.50 to 2.46; <jats:italic>P<\/jats:italic>=0.43). There was a nonsignificant decrease in the QTd between baseline and 2 h (\u22125.1\u00b115.19 ms; 95% CI \u221213.22 to 2.96; <jats:italic>P<\/jats:italic>=0.197) and between baseline and 1 month (\u22120.61\u00b115.04 ms; 95% CI \u22128.1 to 6.87; <jats:italic>P<\/jats:italic>=0.865). A significant increase in the PR interval (7.4\u00b110.7 ms; 95% CI 2.5 to 12.25 ms; <jats:italic>P<\/jats:italic>=0.005) was observed at 1 month.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of ATV did not result in increases in the QTc interval or QTd. However, PR interval monitoring may be warranted in patients with underlying heart block or those treated with atrioventricular nodal blocking agents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2006.00382.x","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T08:22:49Z","timestamp":1148458969000},"page":"317-322","source":"Crossref","is-referenced-by-count":37,"title":["A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV\u2010positive patients"],"prefix":"10.1111","volume":"7","author":[{"given":"AJ","family":"Busti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP","family":"Tsikouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MJ","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SR","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RM","family":"Canham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DM","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,5,24]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"HaasDW ZalaC SchraderSet al. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC) fasting triglyceride (TG) and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy.9th Conference on Retrovirus and Opportunistic Infections. Seattle WA February 2002 [Abstract 42]."},{"key":"e_1_2_6_3_2","article-title":"Atazanavir","author":"Piliero P","journal-title":"A once-daily protease inhibitor with a superior lipid profile: results of clinical trials beyond week 48"},{"key":"e_1_2_6_4_2","unstructured":"Bristol\u2010Myers Squibb. Reyataz (atavanir sulfate) package insert. Princeton NJ 2006."},{"key":"e_1_2_6_5_2","unstructured":"Bristol\u2010Myers Squibb Company. BMS\u2010232632: atazanavir briefing document May 2003. Available fromhttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3950B1_01_BristolMyersSquibb\u2010atazanavir.pdf(accessed 17 April 2006)."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1997.tb05439.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002460010038"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)91081-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01845498"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.389"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199808000-00011"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.3.646"},{"key":"e_1_2_6_13_2","first-page":"878","article-title":"Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection","volume":"55","author":"Vallejo CN","year":"2002","journal-title":"Rev Esp Cardiol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A454"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.57.6.1074"},{"key":"e_1_2_6_16_2","first-page":"379","article-title":"Monophasic action potential mapping in human subjects with normal electrocardiograms","volume":"75","author":"Franz MR","year":"1987","journal-title":"direct evidence for the genesis of the T wave"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.4.1516"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90036-C"},{"key":"e_1_2_6_19_2","first-page":"342","article-title":"QT dispersion","volume":"63","author":"Day CP","year":"1990","journal-title":"an indication of arrhythmia risk in patients with long QT intervals"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90742-0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91164-9"},{"key":"e_1_2_6_22_2","first-page":"511","article-title":"QT interval dispersion","volume":"71","author":"Pye M","year":"1994","journal-title":"a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias?"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.73.1.32"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90697-5"},{"key":"e_1_2_6_25_2","unstructured":"BirnkrantD.Memorandum: Background Package for NDA 21\u2010567. Atazanavir Sulfate. Food and Drug Administration.http:\/\/fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3950B1\u201002_FDA_Atazanavir.htm2003"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.16.2120"},{"key":"e_1_2_6_27_2","first-page":"293","article-title":"Algorithms for computerized QT analysis","volume":"30","author":"Xue Q","year":"1998","journal-title":"J Electrocardiol"},{"key":"e_1_2_6_28_2","first-page":"539","article-title":"Measuring QT dispersion","volume":"77","author":"Murray A","year":"1997","journal-title":"man versus machine"},{"key":"e_1_2_6_29_2","article-title":"Increased incidence of cardiovascular disease in HIV\u2010infected persons in care","author":"Moore RD","journal-title":"10th Conference on Retroviruses and Opportunistic Infections"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11672-2"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030218"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199909000-00005"},{"key":"e_1_2_6_33_2","volume-title":"Reyataz (Atazanavir Sulfate) Package Insert","author":"Bristol\u2010Myers Squibb Company.","year":"2004"},{"key":"e_1_2_6_34_2","first-page":"1339","article-title":"Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy","volume":"17","author":"Haas DW","year":"2003","journal-title":"a randomized comparative pilot trial"},{"key":"e_1_2_6_35_2","unstructured":"DeJesusE GrinsztejnB RodriguezCet al. Effiacy and safety of atazanavir (ATV) with ritonavir or saquinavir (SQV) vs lopinavir\/ritonavir (LPV\/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48\u2010week results from BMS AI424\u2010045.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA February 2004 [Poster J\u201033 547]."},{"key":"e_1_2_6_36_2","unstructured":"El\u2010SaderW ReissP WitSDet al. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex age and lipid changes.12th Conference on Retroviruses and Opportunistic Infections. Boston MA 22\u201325February 2005 [Oral Abstract 42]."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124080-00002"},{"key":"e_1_2_6_38_2","first-page":"2237","article-title":"Age\u2010 and sex\u2010related differences in clinical manifestations in patients with cogenital long QT syndrome","volume":"97","author":"Locati EH","year":"1998","journal-title":"findings from the international LQTS Registry"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510210076031"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2006.00382.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2006.00382.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:06:47Z","timestamp":1696961207000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2006.00382.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,24]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1468-1293.2006.00382.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2006.00382.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,24]]}}}